The trial’s failure is a “stark reminder of just how elusive an HIV vaccine really is and why this kind of research continues to be important,” Jennifer Kates, director of global health and HIV policy at Kaiser Family Foundation, said.Original Article
You may also like
Insurers Hedge on Trump-Backed Pledge To Improve...
Violence Repeatedly Erupts at Dementia Care Facilities...
Leadership Vacuum: Agencies in New York and Beyond...
A Deloitte-Run System Denied Medicaid Benefits for...
Severely Ill Prisoners Granted Early Release Are Left...
Tempus to buy cancer test maker Personalis for $1.5B
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.
